Good Samaritan Hospital, West Islip, NY – Dr. Darakchiev will talk about a rare brain tumor entity: “Central neurocytoma” in a lecture this coming Monday, August 24th.

 

Dr. Darakchiev, a board-certified neurosurgeon with over 20 years of experience invites his colleagues and to join an online discussion.

“I would like to inform all of my colleagues, patients, and everybody involved with the Brain Tumor Program at Good Samaritan Hospital, of our ongoing monthly multidisciplinary comprehensive Neurosurgery/Spine Tumor Board educational discussions.”

 

The initiative has been planned and implemented following the accreditation requirements and policies of the Medical Society of the State of New York (MSSNY) through the joint providership of St. Francis Hospital and Good Samaritan Hospital Medical Center. St. Francis Hospital is accredited by The Medical Society of the State of New York (MSSNY) to provide Continuing Medical Education for physicians.

 

“In addition to discussing brain tumor patients, the Board has expanded to provide further educational content for the attendees – Neurosurgeons, Neurologists, Medical Oncologists, Radiation Oncologists, Radiologists, Pathologists, as well as Nurse Practitioners, Physician Assistants, Medical Students, and guests,” Dr. Darakchiev said.

 

Since May 2020, Dr. Darakchiev has started presenting the Brain Tumor Series lectures online, covering topics like: “Cerebello-Pontine Angle Tumors”, “Current Management of Metastatic Brain Disease” and “Carcinomatous Meningitis”. 

 

Dr. Darakchiev is pleased to invite his colleagues from the multidisciplinary Brain Tumor Program team to the next Brain and Spine Tumor Board lecture this coming Monday, August 24th. He will speak about his patients’ experience with the rare Brain Tumor entity called “Central neurocytoma”.

 

You are welcome to join the discussion! 

 

The “Patient Education” section on our website will give you an insight into the most common neurological conditions. If you require a medical check-up, please contact us.